Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Settings
2.2. Sampling and Recruitment of Hospitals
2.3. Inclusion and Exclusion Criteria
2.4. Case Definition and Data Collection
2.5. Timeline
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Plachouras, D.; Kärki, T.; Hansen, S.; Hopkins, S.; Lyytikäinen, O.; Moro, M.L.; Reilly, J.; Zarb, P.; Zingg, W.; Kinross, P.; et al. Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. Eurosurveillance 2018, 23, 1800393. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saleem, Z.; Saeed, H.; Hassali, M.A.; Godman, B.; Asif, U.; Yousaf, M.; Ahmed, Z.; Riaz, H.; Raza, S.A. Pattern of inappropriate antibiotic use among hospitalized patients in Pakistan: A longitudinal surveillance and implications. Antimicrob. Resist. Infect. Control 2019, 8, 188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gandra, S.; Singh, S.K.; Jinka, D.R.; Kanithi, R.; Chikkappa, A.K.; Sharma, A.; Dharmapalan, D.; Vasudevan, A.K.; Tunga, O.; Akula, A.; et al. Point prevalence surveys of antimicrobial use among hospitalized children in six hospitals in India in 2016. Antibiotics 2017, 6, 19. [Google Scholar] [CrossRef] [PubMed]
- Saleem, Z.; Hassali, M.A.; Godman, B.; Versporten, A.; Hashmi, F.K.; Saeed, H.; Saleem, F.; Salman, M.; Rehman, I.U.; Khan, T.M. Point prevalence surveys of antimicrobial use: A systematic review and the implications. Expert Rev. Anti-Infect. Ther. 2020, 18, 897–910. [Google Scholar] [CrossRef]
- Tillotson, G.S.; Zinner, S.H. Burden of antimicrobial resistance in an era of decreasing susceptibility. Expert Rev. Anti-Infect. Ther. 2017, 15, 663–676. [Google Scholar] [CrossRef] [PubMed]
- Hogan, K.-A.; Gazarin, M.; Lapenskie, J. Development and implementation of an antimicrobial stewardship program in a rural hospital. Can. J. Hosp. Pharm. 2016, 69, 403. [Google Scholar] [CrossRef] [Green Version]
- File, T.M., Jr.; Srinivasan, A.; Bartlett, J.G. Antimicrobial stewardship: Importance for patient and public health. Clin. Infect. Dis. 2014, 59 (Suppl. 3), S93–S96. [Google Scholar] [CrossRef] [Green Version]
- Emeka, P.M.; Al-Omar, M.; Khan, T.M. Public attitude and justification to purchase antibiotics in the Eastern region Al Ahsa of Saudi Arabia. Saudi Pharm. J. 2014, 22, 550–554. [Google Scholar] [CrossRef] [Green Version]
- Memish, Z.A.; Venkatesh, S.; Ahmed, Q.A. Travel epidemiology: The Saudi perspective. Int. J. Antimicrob. Agents 2003, 21, 96–101. [Google Scholar] [CrossRef]
- Ahmed, Q.A.; Arabi, Y.M.; Memish, Z.A. Health risks at the Hajj. Lancet 2006, 367, 1008–1015. [Google Scholar] [CrossRef]
- Al Matar, M.; Enani, M.; Binsaleh, G.; Roushdy, H.; Alokaili, D.; Al Bannai, A.; Khidir, Y.; Al-Abdely, H. Point prevalence survey of antibiotic use in 26 Saudi hospitals in 2016. J. Infect. Public Health 2019, 12, 77–82. [Google Scholar] [CrossRef]
- Versporten, A.; Bielicki, J.; Drapier, N.; Sharland, M.; Goossens, H.; Group, A.P.; Calle, G.M.; Garrahan, J.P.; Clark, J.; Cooper, C.; et al. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: Developing hospital-quality indicators of antibiotic prescribing for children. J. Antimicrob. Chemother. 2016, 71, 1106–1117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Versporten, A.; Zarb, P.; Caniaux, I.; Gros, M.-F.; Drapier, N.; Miller, M.; Jarlier, V.; Nathwani, D.; Goossens, H.; Koraqi, A.; et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. Lancet Glob. Health 2018, 6, e619–e629. [Google Scholar] [CrossRef] [Green Version]
- El Zowalaty, M.; Belkina, T.; Bahashwan, S.A.; Tebbens, J.D.; Abdel-Salam, H.A.; Khalil, A.I.; Daghriry, S.I.; Gahtani, M.A.; Madkhaly, F.M.; Nohi, N.I.; et al. Knowledge, awareness, and attitudes toward antibiotic use and antimicrobial resistance among Saudi population. Int. J. Clin. Pharm. 2016, 38, 1261–1268. [Google Scholar] [CrossRef] [PubMed]
- Skoog, G.; Struwe, J.; Cars, O.; Hanberger, H.; Odenholt, I.; Prag, M.; Skärlund, K.; Ulleryd, P.; Erntell, M. Repeated nationwide point-prevalence surveys of antimicrobial use in Swedish hospitals: Data for actions 2003–2010. Eurosurveillance 2016, 21, 30264. [Google Scholar] [CrossRef]
- Saleem, Z.; Hassali, M.A.; Versporten, A.; Godman, B.; Hashmi, F.K.; Goossens, H.; Saleem, F. A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: Findings and implications. Expert Rev. Anti-Infect. Ther. 2019, 17, 285–293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, H.; Somani, J.; Wu, J.; Foo, G.; Chung, G. The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS): Comparison of results over the years2015–2019. Int. J. Infect. Dis. 2020, 101, 109. [Google Scholar] [CrossRef]
- Hansen, S.; Sohr, D.; Piening, B.; Pena Diaz, L.; Gropmann, A.; Leistner, R.; Meyer, E.; Gastmeier, P.; Behnke, M. Antibiotic usage in German hospitals: Results of the second national prevalence study. J. Antimicrob. Chemother. 2013, 68, 2934–2939. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berild, D.; Ringertz, S.H.; Lelek, M. Appropriate antibiotic use according to diagnoses and bacteriological findings: Report of 12 point-prevalence studies on antibiotic use in a university hospital. Scand. J. Infect. Dis. 2002, 34, 56–60. [Google Scholar] [CrossRef]
- Seaton, R.; Nathwani, D.; Burton, P.; McLaughlin, C.; MacKenzie, A.; Dundas, S.; Ziglam, H.; Gourlay, Y.; Beard, K.; Douglas, E. Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT). Int. J. Antimicrob. Agents 2007, 29, 693–699. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.; Walker, S.A.; Daneman, N.; Elligsen, M.; Palmay, L.; Coburn, B.; Simor, A. Point prevalence survey of antimicrobial utilization in a Canadian tertiary-care teaching hospital. J. Epidemiol. Glob. Health 2015, 5, 143–150. [Google Scholar] [CrossRef] [Green Version]
- Ren, N.; Zhou, P.; Wen, X.; Li, C.; Huang, X.; Guo, Y.; Meng, L.; Gong, R.; Feng, L.; Fu, C.; et al. Point prevalence survey of antimicrobial use in Chinese hospitals in 2012. Am. J. Infect. Control 2016, 44, 332–339. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.; Sengupta, S.; Antony, R.; Bhattacharya, S.; Mukhopadhyay, C.; Ramasubramanian, V.; Sharma, A.; Sahu, S.; Nirkhiwale, S.; Gupta, S.; et al. Variations in antibiotic use across India: Multi-centre study through Global Point Prevalence survey. J. Hosp. Infect. 2019, 103, 280–283. [Google Scholar] [CrossRef] [PubMed]
- Morioka, H.; Hirabayashi, A.; Iguchi, M.; Tomita, Y.; Kato, D.; Sato, N.; Hyodo, M.; Kawamura, N.; Sadomoto, T.; Ichikawa, K.; et al. The first point prevalence survey of health care–associated infection and antimicrobial use in a Japanese university hospital: A pilot study. Am. J. Infect. Control 2016, 44, e119–e123. [Google Scholar] [CrossRef] [PubMed]
- Oduyebo, O.; Olayinka, A.; Iregbu, K.; Versporten, A.; Goossens, H.; Nwajiobi-Princewill, P.; Jimoh, O.; Ige, T.; Aigbe, A.; Ola-Bello, O.; et al. A point prevalence survey of antimicrobial prescribing in four Nigerian tertiary hospitals. Ann. Trop. Pathol. 2017, 8, 42. [Google Scholar] [CrossRef]
- Usluer, G.; Ozgunes, I.; Leblebicioglu, H.; The Turkish Antibiotic Utilization Study Group. A multicenter point-prevalence study: Antimicrobial prescription frequencies in hospitalized patients in Turkey. Ann. Clin. Microbiol. Antimicrob. 2005, 4, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dlamini, N.N.; Meyer, J.C.; Kruger, D.; Kurdi, A.; Godman, B.; Schellack, N. Feasibility of using point prevalence surveys to assess antimicrobial utilisation in public hospitals in South Africa: A pilot study and implications. Hosp. Pract. 2019, 47, 88–95. [Google Scholar] [CrossRef] [Green Version]
- Afriyie, D.K.; Sefah, I.A.; Sneddon, J.; Malcolm, W.; McKinney, R.; Cooper, L.; Kurdi, A.; Godman, B.; Seaton, R.A. Antimicrobial point prevalence surveys in two Ghanaian hospitals: Opportunities for antimicrobial stewardship. JAC-Antimicrob. Resist. 2020, 2, dlaa001. [Google Scholar] [CrossRef] [Green Version]
Characteristics N (%) | H1 | H2 | H3 | H4 | H5 | H6 | Total | Range |
---|---|---|---|---|---|---|---|---|
Hospital Type | ||||||||
Total beds | 175 | 180 | 118 | 174 | 283 | 20 | 950 | 20–283 |
Hospitalized patients | 122 (69.7) | 152 (84.4) | 96 (81.3) | 121 (69.5) | 202 (71.3) | 15 (75.0) | 710 (74.7) | 69.5–84.4 |
Treated patients | 79 (64.7) | 82 (53.9) | 67 (69.8) | 57 (47.1) | 141 (69.8) | 14 (93.3) | 440 (61.9) | 47.1–93.3 |
Prescribed antibiotics (per patient) | 140 (1.7) | 150 (1.8) | 129 (1.9) | 106 (1.8) | 229 (1.6) | 19 (1.3) | 773 (1.7) | 1.3–1.9 |
Departments | ||||||||
Surgical Department | 32 (22.9) | 25 (16.7) | 33 (25.6) | 12 (11.3) | 81 (35.4) | - | 183 (23.7) | 11.3–35.4 |
Medical Department | 74 (52.9) | 125 (83.3) | 39 (30.2) | 71 (67.0) | 106 (46.3) | - | 415 (53.7) | 30.2–83.3 |
Intensive Care Unit | 34 (24.3) | - | 57 (44.2) | 23 (21.7) | 42 (18.3) | 19 (100) | 175 (22.6) | 0–100 |
Gender | ||||||||
Male | 74 (52.9) | 42 (28.0) | 70 (54.3) | 70 (66.0) | 143 (62.4) | 10 (52.6) | 409 (52.9) | 28.0–66.0 |
Female | 66 (47.1) | 105 (70.0) | 54 (41.9) | 36 (34.0) | 86 (37.6) | 9 (47.4) | 356 (46.1) | 34.0–70.0 |
Route of administration | ||||||||
Oral | 13 (9.3) | 15 (10.0) | 5 (3.9) | 12 (11.3) | 25 (10.9) | 5 (26.3) | 75 (9.7) | 3.9–26.3 |
Parenteral | 127 (90.7) | 135 (90.0) | 124 (96.1) | 94 (88.7) | 204 (89.1) | 14 (73.7) | 698 (90.3) | 73.7–96.1 |
Indication | ||||||||
Community-acquired infection | 56 (40.0) | 132 (88.0) | 37 (28.7) | 44 (41.5) | 114 (49.8) | 19 (100.0) | 402 (52.0) | 40.0–100.0 |
Hospital-acquired infection | 73 (52.1) | 18 (12.0) | 27 (20.9) | 40 (37.6) | 60 (26.2) | - | 218 (28.1) | 0.0–52.1 |
Medical prophylaxis | - | - | - | 2 (1.9) | 5 (2.2) | - | 7 (0.9) | 0.0–2.2 |
Surgical prophylaxis (single dose) | 3 (2.1) | - | 4 (3.1) | 5 (4.7) | 7 (3.1) | - | 19 (2.5) | 0.0–4.7 |
Surgical prophylaxis (one day) | 4 (2.9) | - | 13 (10.1) | 4 (3.8) | 11 (4.8) | - | 32 (4.1) | 0.0–10.1 |
Surgical prophylaxis (>1 day) | 4 (2.9) | - | 1 (0.8) | 9 (8.5) | 26 (11.4) | - | 40 (5.2) | 0.0–11.4 |
Others | - | - | 47 (36.5) | 2 (1.9) | 6 (2.6) | - | 55 (7.1) | 0.0–36.5 |
Treatment | ||||||||
Empirical therapy | 108 (77.1) | 143 (95.3) | 107 (82.9) | 89 (84.0) | 194 (84.7) | 19 (100.0) | 660 (85.4) | 77.1–100.0 |
Targeted therapy | 32 (22.9) | 7 (4.7) | 22 (17.1) | 17 (16.0) | 35 (15.3) | - | 113 (14.6) | 0.0–22.9 |
Guideline’s compliance | ||||||||
Yes | 70 (50.0) | 12 (8.0) | 54 (41.9) | 17 (16.0) | 57 (24.9) | 14 (78.9) | 225 (29.1) | 8.0–78.9 |
No | 65 (46.4) | - | 1 (0.8) | 10 (9.4) | 31 (13.5) | 4 (21.1) | 111 (14.4) | 0.0–46.4 |
NA | - | - | 25 (19.4) | 4 (3.8) | 25 (10.9) | - | 54 (7.0) | 0.0–19.4 |
NI | 5 (3.6) | 138 (92.0) | 49 (38.0) | 75 (70.8) | 116 (50.7) | - | 383 (49.5) | 0.0–92.0 |
Stop date documented | 35 (25.0) | 57 (38.0) | 29 (22.5) | 49 (46.2) | 74 (32.3) | 16 (84.2) | 260 (33.6) | 22.5–84.2 |
Reason on notes | 79 (56.4) | 54 (36.0) | 84 (65.1) | 56 (52.8) | 150 (65.5) | 16 (84.2) | 439 (56.8) | 36.0–84.2 |
Culture Reports | 32 | 7 | 22 | 34 | 37 | 0 | 132 | 0–37 |
Antibiotics | n (%) |
---|---|
ANTIBACTERIALS FOR SYSTEMIC USE (J01) | 744 (96.2) |
Tetracyclines (J01A) | 14 (1.8) |
Amphenicols (J01B) | 1 (0.1) |
Penicillins (J01C) | 151 (19.5) |
Cephalosporins and Penams (J01D) | 285 (36.9) |
Sulfonamides and trimethoprim (J01E) | 3 (0.4) |
Macrolides and lincosamides (J01F) | 77 (10.0) |
Aminoglycosides (J01G) | 23 (3.0) |
Quinolones (J01M) | 74 (9.6) |
Other antibacterials (J01X) | 116 (15.0) |
Antimycotics for systemic use(J02) | 8 (1.0) |
Antimycobacterials FOR SYSTEMIC USE (J04) | 11 (1.4) |
Antivirals FOR SYSTEMIC USE (J05) | 8 (1.0) |
Antiprotozoals (P01) | 2 (0.3) |
Top 10 Indications | Top 10 Antibiotics | |||
---|---|---|---|---|
No. | Indications | n (%) | Antibiotics | n (%) |
1 | Pneumonia | 134 (17.3) | Ceftriaxone | 116 (15.0) |
2 | Others | 111 (14.4) | Piperacillin, enzyme inhibitor | 84 (10.9) |
3 | SST | 84 (10.9) | Metronidazole | 55 (7.1) |
4 | Unknown | 67 (8.7) | Cefuroxime | 45 (5.8) |
5 | SEPSIS | 51 (6.6) | Levofloxacin | 45 (5.8) |
6 | OBGY | 42 (5.4) | Meropenam | 42 (5.4) |
7 | BJ | 38 (4.9) | Clindamycin | 41 (5.3) |
8 | CNS | 28 (3.6) | Vancomycin | 37 (4.8) |
9 | CVS | 25 (3.2) | Cefazolin | 35 (4.5) |
10 | P. GIT | 25 (3.2) | Ciprofloxacin | 25 (3.2) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Haseeb, A.; Faidah, H.S.; Algethamy, M.; Alghamdi, S.; Alhazmi, G.A.; Alshomrani, A.O.; Alqethami, B.R.; Alotibi, H.S.; Almutiri, M.Z.; Almuqati, K.S.; et al. Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals. Int. J. Environ. Res. Public Health 2022, 19, 254. https://doi.org/10.3390/ijerph19010254
Haseeb A, Faidah HS, Algethamy M, Alghamdi S, Alhazmi GA, Alshomrani AO, Alqethami BR, Alotibi HS, Almutiri MZ, Almuqati KS, et al. Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals. International Journal of Environmental Research and Public Health. 2022; 19(1):254. https://doi.org/10.3390/ijerph19010254
Chicago/Turabian StyleHaseeb, Abdul, Hani Saleh Faidah, Manal Algethamy, Saleh Alghamdi, Ghaidaa Ali Alhazmi, Afnan Owedah Alshomrani, Bashair Rjyan Alqethami, Hind Saeed Alotibi, Maali Zayed Almutiri, Khawlah Saad Almuqati, and et al. 2022. "Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals" International Journal of Environmental Research and Public Health 19, no. 1: 254. https://doi.org/10.3390/ijerph19010254
APA StyleHaseeb, A., Faidah, H. S., Algethamy, M., Alghamdi, S., Alhazmi, G. A., Alshomrani, A. O., Alqethami, B. R., Alotibi, H. S., Almutiri, M. Z., Almuqati, K. S., Albishi, A. A., Elrggal, M. E., Mahrous, A. J., Khogeer, A. A., Saleem, Z., Iqbal, M. S., & Sheikh, A. (2022). Antimicrobial Usage and Resistance in Makkah Region Hospitals: A Regional Point Prevalence Survey of Public Hospitals. International Journal of Environmental Research and Public Health, 19(1), 254. https://doi.org/10.3390/ijerph19010254